Clinical Trials Logo

Dengue Virus clinical trials

View clinical trials related to Dengue Virus.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05507450 Active, not recruiting - Dengue Virus Clinical Trials

Safety and Immunogenicity of Three V181 Dengue Vaccine Potencies in Adults (V181-003)

Start date: September 7, 2022
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to compare the dengue virus-neutralizing antibody geometric mean titers (GMTs) for each of the 4 dengue serotypes (DENV1, DENV2, DENV3, and DENV4) at Day 28 post-vaccination for participants administered the V181 Low-Potency Level vaccine versus the V181 Mid-Potency Level vaccine. This study will also evaluate the safety and tolerability of 3 different V181 potency level vaccines. The primary hypothesis of the study is that the V181 Low-Potency Level vaccine is non-inferior to the V181 Mid-Potency Level vaccine for each of the 4 dengue serotypes based on GMTs at Day 28 post-vaccination.

NCT ID: NCT03141138 Active, not recruiting - Dengue Virus Clinical Trials

Comparison of Tetravalent Dengue Virus Purified Inactivated Vaccine and Tetravalent Dengue Virus Live Attenuated Vaccine

Start date: November 8, 2017
Phase: Phase 1
Study type: Interventional

This study is a Phase 1, randomized, open-label study of the prime-boost vaccine candidates given in the prime-boost regimen previously demonstrated to have a high level of immunogenicity and immune durability: Day 0 prime (PIV) and Day 180 boost (LAV), and compare it with a previously untested schedule: Day 0 prime (PIV) and Day 90 boost (LAV) in order to define the potential tradeoff between potential immunogenicity, including cell-mediated immunity, and a more practical dosing schedule.